CDLX (Cardlytics) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Cardlytics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cardlytics is: High Risk: High uncertainty.

Competitive Comparison of Cardlytics's Risk Assessment

For the Advertising Agencies subindustry, Cardlytics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardlytics's Risk Assessment Distribution in the Media - Diversified Industry

For the Media - Diversified industry and Communication Services sector, Cardlytics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cardlytics's Risk Assessment falls into.

Cardlytics (NAS:CDLX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cardlytics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cardlytics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardlytics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Communication Services » Media - Diversified » Cardlytics Inc (NAS:CDLX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0LEC:UK CYX:Germany

Address

675 Ponce de Leon Avenue NE, Suite 4100, Atlanta, GA, USA, 30308

Website

https://www.cardlytics.com

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

Executives

Clifford Sosin	10 percent owner	8 WRIGHT STREET, 1ST FL, WESTPORT CT 06880
Alexis Desieno	officer: Chief Financial Officer	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Amit Gupta	officer: Chief Operating Officer	C/O CARDLYTICS, INC, 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Nicholas Hollmeyer Lynton	officer: Chief Legal & Privacy Officer	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Klinck John L. Jr.	director	C/O STATE STREET CORPORATION, ONE LINCOLN STREET, BOSTON MA 02111
Scott A Hill	director	INTERCONTINENTALEXCHANGE, INC., 2100 RIVEREDGE PKWY. STE. 500, ATLANTA GA 30328
Karim Saad Temsamani	director, officer: Chief Executive Officer	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Alex Mishurov	director	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVE. NE, SUITE 6000, ATLANTA GA 30308
Andrew Christiansen	officer: Chief Financial Officer	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Chris Suh	director	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVE. NE, STE 6000, ATLANTA GA 30308
Jessica Jensen	director	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
John V Balen	director
Scott D. Grimes	director, officer: Chief Executive Officer	CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Lynne Marie Laube	director, officer: Chief Operating Officer	C/O CARDLYTICS, INC., 675 PONCE DE LEON AVENUE NE, SUITE 6000, ATLANTA GA 30308
Kirk Somers	officer: Chief Legal & Privacy Officer